PMID: 15232337Jul 3, 2004Paper

Naltrexone treatment of tardive dyskinesia in patients with schizophrenia

Journal of Clinical Psychopharmacology
Ikwunga WonodiGunvant K Thaker

Abstract

Treatment of dyskinetic disorders, in general, and of tardive dyskinesia (TD), in particular, is difficult. The opiate peptide enkephalin coexits with gamma aminobutyric acid in the projection neurons of striatum forming the "indirect" pathway. Several lines of preclinical evidence implicate this enkephalin-comediated pathway in the pathophysiology and therapeutics of dyskinesia. However, previous studies, most using relatively low doses of opioid antagonists, showed mixed results. The goal of the current study was to test whether moderately high doses of naltrexone, alone or in combination with a subtherapeutic dose of a gamma aminobutyric acid agonist, improve TD. In 2 double-blind, placebo-controlled, randomized, crossover trials, effects of naltrexone alone (n = 9) and in combination with clonazepam (n = 14) were tested on TD. In both trials, patients' antipsychotic medication and dose remained unchanged through the trial. Naltrexone dose was increased over a period of 3 weeks to 200 mg/d and maintained at that dose for another week. In the second study, patients were first stabilized on low dose (0.25 to 0.5 mg) of clonazepam for 4 weeks or longer. In addition to the TD scores, saccadic peak velocity and latency, as measur...Continue Reading

References

Oct 1, 1992·Clinical Pharmacology and Therapeutics·A L van SteveninckA F Cohen
May 1, 1992·Annals of Neurology·G Erenberg, R J Lederman
Jul 1, 1990·Trends in Neurosciences·M R DeLong
Jan 1, 1987·Psychopharmacology·I BlumE Roberts
Dec 1, 1985·Biological Psychiatry·R Sandyk, S R Snider
Apr 1, 1982·Archives of General Psychiatry·G F JohnsonJ M Rey
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, J M Kane
Jan 1, 1982·Annals of the New York Academy of Sciences·J VolavkaG Koz
Oct 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·A J StoesslH Frydryszak
Jul 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·O RascolA Rascol
Oct 24, 2000·Schizophrenia Research·G K ThakerJ Sherr
Mar 20, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·A J MansonA J Lees
Apr 4, 2001·The International Journal of Neuropsychopharmacology·Robin A. EmsleyDan J. Stein
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin McCreadie

❮ Previous
Next ❯

Citations

Mar 17, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Igor ElmanScott E Lukas
Jul 15, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Pierluigi Onali, Maria C Olianas
Dec 1, 2006·Schizophrenia Bulletin·Bruce I TuretskyNeal R Swerdlow
Feb 16, 2005·Expert Opinion on Drug Safety·Robert L Rodnitzky
Apr 9, 2013·Frontiers in Neuroendocrinology·Flavia di MichelePatrizia Longone
Nov 25, 2004·Brain Research Bulletin·Nilza P AraujoRoberto Frussa-Filho
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
Jan 21, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Jun 10, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Samuel D ClarkAnissa Abi-Dargham
Jun 14, 2003·The Cochrane Database of Systematic Reviews·K V Soares-Weiser, C Joy
Mar 20, 2018·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserHanna Bergman
Jul 21, 2006·The Cochrane Database of Systematic Reviews·P S Bhoopathi, K Soares-Weiser
May 5, 2000·The Cochrane Database of Systematic Reviews·J J McGrath, K V Soares

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.